CESSATECH A/S DK -20
Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company's lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel.… Read more
CESSATECH A/S DK -20 (8GN) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CESSATECH A/S DK -20 (8GN) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CESSATECH A/S DK -20 - Net Assets Trend (None–None)
This chart illustrates how CESSATECH A/S DK -20's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CESSATECH A/S DK -20 (None–None)
The table below shows the annual net assets of CESSATECH A/S DK -20 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CESSATECH A/S DK -20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CESSATECH A/S DK -20 Competitors by Market Cap
The table below lists competitors of CESSATECH A/S DK -20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kairos Minerals Limited
PINK:KAIFF
|
$37.39 Million |
|
Summa Defence Oyj
HE:SUMMA
|
$37.41 Million |
|
Kolon Global Corp
KO:003075
|
$37.41 Million |
|
Tobii AB
PINK:TBIIF
|
$37.41 Million |
|
Powertech Industrial Co Ltd
TW:3296
|
$37.37 Million |
|
Outset Medical Inc
NASDAQ:OM
|
$37.37 Million |
|
SEOHAN Const. & Eng.co.Ltd
KQ:011370
|
$37.37 Million |
|
NVH Korea Inc
KQ:067570
|
$37.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CESSATECH A/S DK -20's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CESSATECH A/S DK -20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CESSATECH A/S DK -20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CESSATECH A/S DK -20's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CESSATECH A/S DK -20 (8GN) | €- | N/A | N/A | $37.39 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |